SCHEDULE 13D/A
SCHEDULE 13D/ASchedule 13D ownership disclosure
NEWAMSTERDAM PHARMA COMPANY
Ordinary Shares, nominal value EUR0.12 per share · CUSIP: N62509109
Event date: 2025-08-18
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Frazier Life Sciences X, L.P.Reported CIK 0001790879
Shares: 7,327,937.00 · Class: 6.5%
- Frazier Lifesciences Sponsor LLCReported CIK 0001828906
Shares: 3,968,000.00 · Class: 3.5%
- FHMLS X, L.P.Reported CIK 0001790880
Shares: 7,327,937.00 · Class: 6.5%
- FHMLS X, L.L.C.Reported CIK 0001790811
Shares: 7,327,937.00 · Class: 6.5%
- Frazier Life Sciences Public Fund, L.P.Reported CIK 0001863769
Shares: 5,587,957.00 · Class: 5.0%
- FHMLSP, L.P.Reported CIK 0001879466
Shares: 5,587,957.00 · Class: 5.0%
- FHMLSP, L.L.C.Reported CIK 0001879465
Shares: 5,587,957.00 · Class: 5.0%
- Frazier Life Sciences Public Overage Fund, L.P.Reported CIK 0001913804
Shares: 2,975,757.00 · Class: 2.6%
- FHMLSP Overage, L.P.Reported CIK 0001963247
Shares: 2,975,757.00 · Class: 2.6%
- FHMLSP Overage, L.L.C.Reported CIK 0001963248
Shares: 2,975,757.00 · Class: 2.6%
- Frazier Life Sciences XI, L.P.Reported CIK 0001911592
Shares: 1,174,815.00 · Class: 1.0%
- FHMLS XI, L.P.Reported CIK 0001911580
Shares: 1,174,815.00 · Class: 1.0%
- FHMLS XI, L.L.C.Reported CIK 0001911623
Shares: 1,174,815.00 · Class: 1.0%
- Frazier Life Sciences XII, L.P.Reported CIK 0002052255
Shares: 59,647.00 · Class: 0.1%
- FHMLS XII, L.P.Reported CIK 0002052246
Shares: 59,647.00 · Class: 0.1%
- FHMLS XII, L.L.C.Reported CIK 0002052177
Shares: 59,647.00 · Class: 0.1%
- James N. TopperReported CIK 0001341382
Shares: 7,327,937.00 · Class: 6.5%
- Patrick J. HeronReported CIK 0001365617
Shares: 7,327,937.00 · Class: 6.5%
- Albert ChaReported CIK 0001397906
Shares: 0.00 · Class: 0.0%
- James BrushReported CIK 0001865123
Shares: 0.00 · Class: 0.0%
- Daniel EstesReported CIK 0001702527
Shares: 0.00 · Class: 0.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001415889-25-022506
- Form type
- SCHEDULE 13D/A
- Filer
- Frazier Life Sciences X, L.P.
- CIK
- CIK 1790879
- Filed
- Aug 20, 2025
- Reporting period
- Aug 18, 2025
- Description
- Schedule 13D beneficial ownership